Author’s response to reviews

Title: Relapsing MAP-Kinase Inhibitor-Induced Pneumonitis, a case report.

Authors:

Violaine Giraud (violaine.giraud@apr.aphp.fr)
Christine Longvert (christine.longvert@apr.aphp.fr)
Solène Houlle-Crepin (solenehoulle@hotmail.com)
Claire Danel (claire.danel@bch.aphp.fr)
Sylvie Labrune (sylvie.labrune@apr.aphp.fr)
Philippe Camus (philippecamus1@gmail.com)
Philippe Saiag (philippe.saiag@uvSQ.fr)
Thierry Chinet (thierry.chinet@apr.aphp.fr)

Version: 2
Date: 12 December 2014

Author’s response to reviews: see over
Dear Editor,

Please, find attached a revised manuscript entitled **Relapsing MAP-Kinase Inhibitor-Induced Pneumonitis, a case report** after editorial office comments.

This case is original because it reports a potentially serious pulmonary side effect of anti-cancer drugs for the first time. It describes two sequential episodes of pneumonitis attributed to trametinib (a MEK inhibitor) and then to vemurafenib (a BRAF inhibitor) in a patient treated for metastatic melanoma. In addition, we provide histological findings.

Inhibition of BRAF and MEK in the MAP tyrosine Kinase pathway is currently one of the most promising therapeutic options for patients with melanoma and these drugs are currently under development for other solid tumors. We believe it is important to alert clinicians to the potential pulmonary toxicity of these drugs and to their possible class effect.

**Competing interests**

V. Giraud, C. Longvert, S. Houille-Crepin, C. Danel, S. Labrune, Ph. Camus and Th. Chinet have no competing interests. Ph. Saiag received research grants and clinical research or consultancy fees from GSK, Roche-Genentech, BMS and Novartis.
Authors’ contributions

V. Giraud, C. Longvert and S. Houlle-Crepin, helped to draft the manuscript. S. Houlle-Crepin and C. Danel did the histologic analysis. S. Labrune, Ph. Camus and Th. Chinet reviewed the manuscript. All authors read and approved the final manuscript.

This paper represents original material that has not been published and is not considered for publication in another journal. All authors participated to the case report preparation and review.

After comments from Annie Lyn Bravo of the editorial office, changes have been made:

- an authors’ contribution section in this cover letter
- line numbering in the manuscript

We hope our paper will be considered suitable for publication in your journal.

Sincerely Yours,

Dr Violaine Giraud